UR8.F
UroGen Pharma Ltd.
FrankfurtEUREQUITY
Healthcare
DELAYED
Last price
39.20
▲ 0.04 (0.10%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
39.20
Prev close
39.16
Day high
39.20
Day low
39.20
Volume
345
Market cap
$1.92B
P/E (TTM)
—
52W range
13.80 – 42.90
Day trading desk
Gap from prior close
+0.10%
Prior close 39.16
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
39.20 – 39.20
Position in range
—
—
ATR (14D)
1.64
4.19% of price
Prior day high
39.16
PDH
Prior day low
39.16
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 19
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.45%
-2.3%
1M
+6.26%
+2.9%
3M
+58.45%
+56.0%
6M
+125.29%
+113.3%
YTD
+103.11%
+91.1%
1Y
+141.98%
+121.7%
3Y
+355.81%
+280.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on UR8.F open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 9, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $400.00K | Direct |
| Jun 22, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $350.10K | Direct |
| Jun 8, 26 | SCHOENBERG MARK Officer |
SELL | 5.22K | $142.56K | Direct |
| Jun 8, 26 | SCHOENBERG MARK Officer |
— | 10.00K | — | Direct |
| May 26, 26 | ROBINSON JAMES A JR. Director |
— | 2.00K | — | Direct |
| May 8, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $300.00K | Direct |
| Feb 3, 26 | SCHOENBERG MARK Officer |
SELL | 7.37K | $145.17K | Direct |
| Feb 3, 26 | SMITH JASON DREW General Counsel |
SELL | 7.48K | $147.26K | Direct |
| Jan 30, 26 | SCHOENBERG MARK Officer |
— | 13.33K | — | Direct |
| Jan 30, 26 | SMITH JASON DREW General Counsel |
— | 15.50K | — | Direct |
| Nov 26, 25 | WEN LEANA Director |
— | 2.00K | — | Direct |
| Nov 26, 25 | WILDMAN DANIEL GEORGE Director |
— | 2.00K | — | Direct |
| Nov 26, 25 | BUTITTA CYNTHIA M Director |
— | 2.00K | — | Direct |
| Nov 26, 25 | ROBINSON JAMES A JR. Director |
— | 2.00K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUTITTA CYNTHIA M |
Director | 2.00K | Conversion of Exercise of derivative security |
DEGNAN CHRISTOPHER |
Chief Financial Officer | 2.28K | Sale |
HOLDEN STUART M.D. |
Director | 2.00K | Conversion of Exercise of derivative security |
KIM DONG |
Chief Financial Officer | 37.75K | Conversion of Exercise of derivative security |
ROBINSON JAMES A JR. |
Director | 6.00K | Conversion of Exercise of derivative security |
SCHOENBERG MARK |
Officer | 119.76K | Sale |
SMITH JASON DREW |
General Counsel | 55.59K | Sale |
WEN LEANA |
Director | 2.00K | Conversion of Exercise of derivative security |
WILDMAN DANIEL GEORGE |
Director | 2.00K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.92B
Enterprise value$2.00B
Revenue (TTM)$188.73M
Gross profit$171.46M
EBITDA$-66.34M
Net income$-97.64M
EPS (TTM)$-1.68
Free cash flow$-106.98M
Total cash$107.97M
Total debt$196.13M
Book value / share$-2.34
Shares outstanding48.88M
Float43.35M
Short % of float—
Dividend yield—
Beta (5Y)1.58
Valuation & profitability ratios
Trailing P/E—
Forward P/E-10.68
PEG ratio—
Price / sales—
Price / book—
EV / revenue10.61
EV / EBITDA-30.18
Gross margin90.84%
Operating margin0.15%
Profit margin-51.73%
Return on equity—
Return on assets-18.06%
Debt / equity—
Current ratio3.80
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Operating revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | +40.2% |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | +19.4% |
| Research & development | $67.11M | $57.15M | $45.61M | $52.91M | +17.4% |
| Selling, general & admin | $155.10M | $121.15M | $93.27M | $82.84M | +28.0% |
| Total operating expense | $222.20M | $178.30M | $138.89M | $135.74M | +24.6% |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -29.0% |
| Net interest income | -$27.88M | -$27.03M | -$33.63M | -$29.06M | -3.2% |
| Pre-tax income | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -23.7% |
| Tax provision | $78.00K | $2.83M | $3.92M | $1.75M | -97.2% |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Net income to common | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Basic EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| Diluted EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| EBIT | -$138.07M | -$111.52M | -$83.61M | -$99.59M | -23.8% |
| EBITDA | -$135.66M | -$110.33M | -$81.90M | -$97.77M | -23.0% |
| Basic shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Diluted shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $110.75M | $171.99M | $95.00M | $55.41M | -35.6% |
| Cash & short-term investments | $120.46M | $236.69M | $136.97M | $99.96M | -49.1% |
| Accounts receivable | $33.08M | $20.30M | $15.44M | $12.70M | +62.9% |
| Inventory | $16.46M | $9.23M | $5.67M | $4.33M | +78.4% |
| Total current assets | $186.02M | $276.13M | $169.19M | $128.91M | -32.6% |
| Property, plant & equipment | $9.09M | $3.79M | $2.36M | $3.75M | +140.0% |
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | -29.8% |
| Total current liabilities | $46.42M | $45.95M | $31.21M | $23.92M | +1.0% |
| Long-term debt | $122.21M | $121.73M | $98.55M | $97.54M | +0.4% |
| Total debt | $128.33M | $123.39M | $99.39M | $99.12M | +4.0% |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | +3.9% |
| Retained earnings | -$959.72M | -$806.22M | -$679.35M | -$577.10M | -19.0% |
| Shareholder equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Working capital | $139.61M | $230.19M | $137.97M | $104.99M | -39.4% |
| Net tangible assets | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Shares issued | 48.35M | 42.23M | 32.49M | 23.13M | +14.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Depreciation & amortisation | $2.41M | $1.19M | $1.71M | $1.82M | +103.3% |
| Stock-based compensation | $11.96M | $13.11M | $9.34M | $10.58M | -8.8% |
| Change in working capital | -$27.91M | $4.93M | $3.34M | -$6.31M | -665.9% |
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -67.9% |
| Capital expenditure | -$289.00K | -$295.00K | -$194.00K | -$254.00K | +2.0% |
| Investing cash flow | $61.56M | -$20.61M | -$953.00K | $1.06M | +398.6% |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | -79.5% |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -67.7% |
| End cash position | $112.09M | $173.06M | $95.82M | $56.22M | -35.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Operating revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Cost of revenue | $6.57M | $4.14M | $3.29M | $3.28M | $3.55M | +58.8% |
| Gross profit | $65.88M | $46.82M | $34.55M | $24.20M | $20.66M | +40.7% |
| Research & development | $17.34M | $15.60M | $14.31M | $14.01M | $18.91M | +11.1% |
| Selling, general & admin | $48.44M | $51.49M | $39.35M | $37.58M | $43.20M | -5.9% |
| Total operating expense | $65.77M | $67.08M | $53.66M | $51.59M | $62.11M | -2.0% |
| Operating income | $111.00K | -$20.26M | -$19.11M | -$27.39M | -$41.45M | +100.5% |
| Net interest income | -$8.49M | -$7.76M | -$7.52M | -$6.82M | -$7.10M | -9.4% |
| Pre-tax income | -$8.72M | -$28.35M | -$26.64M | -$34.40M | -$48.92M | +69.2% |
| Tax provision | $5.63M | -$4.77M | -$275.00K | -$1.05M | $1.01M | +218.0% |
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Net income to common | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Basic EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| Diluted EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| EBIT | -$3.83M | -$24.16M | -$22.87M | -$31.03M | -$44.79M | +84.1% |
| EBITDA | -$3.17M | -$23.51M | -$22.19M | -$30.39M | -$44.20M | +86.5% |
| Basic shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Diluted shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.13M | $109.97M | $110.75M | $90.04M | $92.90M | -28.0% |
| Cash & short-term investments | $107.97M | $140.27M | $120.46M | $127.03M | $156.95M | -23.0% |
| Accounts receivable | $88.76M | $55.41M | $33.08M | $19.70M | $19.65M | +60.2% |
| Inventory | $24.59M | $20.92M | $16.46M | $8.34M | $7.13M | +17.5% |
| Total current assets | $235.43M | $237.46M | $186.02M | $168.55M | $196.87M | -0.9% |
| Property, plant & equipment | $8.22M | $8.56M | $9.09M | $9.18M | $6.24M | -3.9% |
| Total assets | $252.59M | $253.69M | $200.46M | $185.05M | $208.72M | -0.4% |
| Total current liabilities | $61.91M | $50.63M | $46.42M | $42.24M | $47.55M | +22.3% |
| Long-term debt | $188.73M | $189.53M | $122.21M | $122.11M | $122.51M | -0.4% |
| Total debt | $196.13M | $195.18M | $128.33M | $128.35M | $125.92M | +0.5% |
| Total liabilities | $384.99M | $377.94M | $305.93M | $300.45M | $302.09M | +1.9% |
| Retained earnings | -$997.64M | -$983.29M | -$959.72M | -$933.35M | -$900.00M | -1.5% |
| Shareholder equity | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Working capital | $173.51M | $186.83M | $139.61M | $126.30M | $149.32M | -7.1% |
| Net tangible assets | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Shares issued | 48.72M | 48.71M | 48.35M | 46.78M | 46.20M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Depreciation & amortisation | $668.00K | $652.00K | $679.00K | $639.00K | $596.00K | +2.5% |
| Stock-based compensation | $5.33M | $4.63M | $3.13M | $3.03M | $2.73M | +15.2% |
| Change in working capital | -$24.57M | -$30.08M | -$17.06M | -$13.50M | $5.24M | +18.3% |
| Operating cash flow | -$33.01M | -$45.32M | -$38.33M | -$42.27M | -$39.83M | +27.2% |
| Capital expenditure | -$60.00K | -$54.00K | -$17.00K | -$87.00K | -$141.00K | -11.1% |
| Investing cash flow | $1.67M | -$20.69M | $27.72M | $31.40M | $28.41M | +108.1% |
| Financing cash flow | $500.00K | $65.20M | $31.32M | $8.27M | $296.00K | -99.2% |
| Free cash flow | -$33.07M | -$45.37M | -$38.34M | -$42.36M | -$39.97M | +27.1% |
| End cash position | $80.46M | $111.30M | $112.09M | $91.39M | $93.99M | -27.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $90.58M | +229.6% |
| Next quarter | — | — | $108.23M | +186.0% |
| Current year | — | — | $322.20M | +193.5% |
| Next year | — | — | $541.49M | +68.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders3.60%
Held by institutions100.08%
Institutions holding252
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
40.92
-4.20% from price
SMA 20
38.45
+1.94% from price
SMA 50
34.78
+12.72% from price
SMA 100
28.25
+38.77% from price
SMA 200
23.15
+69.36% from price
EMA 12
39.94
-1.84% from price
EMA 26
38.05
+3.01% from price
EMA 50
34.92
+12.27% from price
RSI (14)
53.8
Neutral
MACD (12,26,9)
1.88
Hist -0.23
ATR (14)
1.64
4.19% of price
Realised vol 30D
77.7%
Annualised
Bollinger upper
44.98
20, 2σ
Bollinger lower
31.92
20, 2σ
50 / 200 cross
Golden
34.78 vs 23.15
Trend bias
Above 200
+69.36%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.40
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
77.7%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-42.0%
Peak to trough
Max drawdown 5Y
-84.2%
Peak to trough
ATR 14
1.64
4.19% of price
Beta (reported)
1.58
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 5, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 21, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Oppenheimer | MAINTAINED | Outperform | Outperformer |
| Jun 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 31, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 2, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 23, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
Headlines
Down 40% on AI Pressure, Michael Burry Says Alibaba Needs to Still Fall by Half
24/7 Wall St. · 4m ago
Prime Minister Carney participates in a virtual meeting in support of Ukraine
CNW Group · 4m ago
NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats
TMX Newsfile · 6m ago
Zillow, Redfin Settle FTC, State Lawsuit Over Rental Partnership
MT Newswires · 7m ago
From Low Cost to High Trust: How China's Hotel Linen Supply Chain Is Changing Global Procurement
PR Newswire · 7m ago
Motorola Completes D-Fend Buyout: Can It Buoy Growth Prospects?
Zacks · 7m ago
AI Video Is Moving Beyond Prompts: Flova Brings "All in One" to Agent-Native Video Creation
PR Newswire · 7m ago
Gemini Expands Prediction Market Offering
CryptoProwl · 7m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.